Atopic Dermatitis
Conditions
Interventions
Observation group:None
Sponsors
Dermatology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Age 18-40 years old, regardless of gender. 1. Patients with a clear diagnosis of atopic dermatitis, meeting the Hanifin-Rajka and Williams diagnostic criteria. Diagnosis is made based on rash characteristics, medical history, past history, family history, combined with pathological and imaging techniques. The admission diagnosis must be confirmed by two associate chief physicians or chief physicians; 2. Enrolled patients are classified by EASI score including moderate and severe chronic patients ; 3. Before treatment, the area of a single skin lesion on the face, neck, chest, or back of the patient is >=15 cm^2; 4.Females of childbearing potential must have a negative pregnancy test at screening and the start of visits; 5. All patients must sign an informed consent form, voluntarily participate in the study, and be able to understand and complete study-related questionnaires.
Exclusion criteria
Exclusion criteria: 1.Individuals with severe mental/neurological symptoms or cognitive impairment who are unable to cooperate with the investigation. 2. Individuals with severe malnutrition, malignant tumors (except completely treated and cured non-metastatic cutaneous squamous or basal cell carcinoma, or in-situ melanoma), infectious diseases (such as hepatitis B, tuberculosis, syphilis, AIDS, hepatitis C, etc.), or other severe systemic diseases. 3. Pregnant or lactating women, or those planning to become pregnant within 3 months. 4. Individuals who have had other skin diseases within 6 months prior to screening that may affect the test results (such as psoriasis, drug-induced dermatitis, erythroderma, contact dermatitis, bullous diseases, severe skin infections, etc.). 5. Medication history: Those who have used topical or systemic antibiotics or antifungal drugs at the affected site within 2 weeks prior to sampling; those who have received systemic immunosuppressive therapy, phototherapy, or systemic biologic agents within 12 weeks prior to sampling (specifically determined based on the half-life of different biological agents).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EASI score;Skin barrier function; | — |
Secondary
| Measure | Time frame |
|---|---|
| NRS score;IGA score;Serum type 2 inflammatory cytokines; | — |
Countries
China
Contacts
Public ContactLv Ping
Dermatology Hospital of Southern Medical University
Outcome results
None listed